Law360, New York (May 08, 2012, 7:48 PM ET) -- U.S. Food and Drug Administration drug reviewers said Tuesday that Arena Pharmaceuticals had eased concerns about potential cancer risks associated with its obesity drug lorcaserin, but said a high risk of heart valve disease could not be ruled out.
The reviewers provided the update in a 246-page briefing document ahead of a FDA advisory committee meeting Thursday to discuss the safety and efficacy of lorcaserin, a drug to help obese patients lose weight.
Lorcaserin was earlier linked to mammary gland tumors in both sexes in a...
Arena Faces New FDA Worries Over Weight-Loss Drug
To view the full article, take a free trial now.
